Clinical trial
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
NCT00436215 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00436215 |
|---|---|
| Title | Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer |
| Official title | A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasm, Fallopian Tube Cancer, Primary Peritoneal Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, BAY 43-9006 |
| Enrollment | 55 |
| Start date | Dec 12, 2006 |
| Primary completion | Jun 26, 2014 |
| Completion | Sep 27, 2014 |
| First posted | Feb 19, 2007 |
| Last update posted | Nov 23, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: